https://www.ncbi.nlm.nih.gov/m/pubmed/30428925/

Dog survey in Russian veterinary hospitals: tick identification and molecular detection of tick-borne pathogens.

Livanova NN, et al. Parasit Vectors. 2018.

Abstract

BACKGROUND: Species of Canidae in Russia can be infested with up to 24 different tick species; however, the frequency of different tick species infesting domestic dogs across Russia is not known. In addition, tick-borne disease risks for domestic dogs in Russia are not well quantified. The goal of this study was to conduct a nationwide survey of ticks collected from infested dogs admitted to veterinary clinics in Russian cities and to identify pathogens found in these ticks.

METHODS: Ticks feeding on dogs admitted to 32 veterinary clinics in 27 major cities across Russia were preserved in ethanol and submitted to a central facility for examination. After identification, each tick was evaluated for infection with known tick-borne pathogens using PCR.

RESULTS: There were 990 individual ticks collected from 636 dogs. All collected ticks belonged to the Ixodidae (hard ticks) and represented 11 species of four genera, Dermacentor, Ixodes, Rhipicephalus and Haemaphysalis. Four most common tick species were D. reticulatus, followed by I. persulcatus, I. ricinus and R. sanguineus. Ixodes persulcatus ticks were found to be infected with 10 different pathogens, and ticks of this species were more frequently infected than either D. reticulatus or I. ricinus. Ixodes persulcatus females were also more frequently co-infected with two or more pathogens than any other tick.

Pathogenic species of five genera were detected in ticks:

  • Anaplasma centrale, A. phagocytophilum & A. marginale (Anaplasma)
  • Babesia canis, B. microti, B. venatorum, B. divergens, B. crassa & B. vogeli (Babesia)
  • Borrelia miyamotoi, B. afzelii and B. garinii (Borrelia)
  • Ehrlichia muris, E. canis and E. ruminantu (Ehrlichia)
  • Theileria cervi (Theileria – a parasitic protozoan)
Anaplasma marginale, E. canis, B. crassa, B. vogeli and T. cervi were detected in I. persulcatus, and Babesia canis in D. marginatum, for the first time in Russia.

CONCLUSIONS: Multiple ticks from four genera and 11 species of the family Ixodidae were collected from domestic dogs across Russia. These ticks commonly carry pathogens and act as disease vectors. Ixodes persulcatus ticks present the greatest risk for transmission of multiple arthropod-borne pathogens.

_________________

**Comment**

It’s getting harder and harder for The Cabal to hide the polymicrobial nature of Lyme/MSIDS.  The data just keeps pouring in:  https://madisonarealymesupportgroup.com/2018/10/30/study-shows-lyme-msids-patients-infected-with-many-pathogens-and-explains-why-we-are-so-sick/

For the first time, Garg et al. show a 85% probability for multiple infections including not only tick-borne pathogens but also opportunistic microbes such as EBV and other viruses.

I’m thankful they included Bartonella as that one is often omitted but definitely a player. I’m also thankful for the mention of viruses as they too are in the mix. The mention of the persister form must be recognized as well as many out there deny its existence.

Key Quote: “Our findings recognize that microbial infections in patients suffering from TBDs do not follow the one microbe, one disease Germ Theory as 65% of the TBD patients produce immune responses to various microbes.”

But there is another important point.

According to this review, 83% of all commercial tests focus only on Lyme (borrelia), despite the fact we are infected with more than one microbe.

And those tests miss half of all cases:  

https://madisonarealymesupportgroup.com/2018/09/12/lyme-testing-problems-solutions/  ...with the C6 Elisa its around 50% sensitive (in the context of the two tiered testing system on its own it has a sensitivity of 75%) because it misses about half of true positive cases….The Western Blot also has many problems with sensitivity at all stages but especially within the first month and again later on the more chronic it becomes.If you take the terrible sensitivity of both tests in the two tiered system you will start to see how testing positive consecutively on both is very unlikely, mathematically improbable and biologically almost impossible unless you are in the HLA autoimmune group which is comparatively rare.

https://madisonarealymesupportgroup.com/2018/01/16/2-tier-lyme-testing-missed-85-7-of-patients-milford-hospital/  Dr. Sin Lee identifying faulty serology tests for Lyme disease in 85.7% of the walk-in patients in the Emergency Room of Milford Hospital.

Please note that all the studies showing the polymicrobial nature of tick borne illness  are foreign.

The Cabal has everyone in the U.S. in a head-lock.

Will the real researchers please stand up and be counted?

 

 

 

 

 

 

 

 

 

https://articles.mercola.com/sites/articles/archive/2018/12/09/retrovirus.aspx?

Plague: One Scientist’s Intrepid Search for the Truth About Human Retroviruses and Chronic Disease

 Approx 3 Min

Written by Dr. Joseph Mercola

Story at-a-glance

  • A retrovirus is a virus that contains RNA encoded genes rather than DNA. Using reverse transcriptase, the retrovirus is able to transform the single-stranded RNA into a double-stranded DNA
  • When the retrovirus infects a host, it integrates its DNA into the DNA of the host cell, which allows the retrovirus to replicate itself and spread through the host
  • One example of a transmissible retrovirus is the HIV virus, which can cascade into the clinical symptoms of acquired immunodeficiency syndrome (AIDS)
  • A retrovirus family known as xenotropic murine leukemia virus-related viruses (XMRV) may play a causal role in chronic fatigue syndrome, chronic myalgic encephalopathy (ME) and other diseases, including autism
  • Some retroviruses, including XMRV (but not HIV as far as we know), infect your germ cells, which means they are transmitted to your offspring

Judy Mikovits, Ph.D., a virologist, researcher and founding research director of the Whittemore Peterson Institute — which researches and treats chronic fatigue syndrome (CFS) in Reno, Nevada — got embroiled in controversy when, in 2009, she was the senior author on a paper which reported that a retrovirus known as xenotropic murine leukemia virus-related virus (XMRV) may play a causal role in CFS and other diseases, including autism.

Her book, “Plague: One Scientist’s Intrepid Search for the Truth About Human Retroviruses and Chronic Fatigue Syndrome (ME/CFS), Autism and Other Diseases,” details her research and personal trials that arose as a consequence of her work.

“Kent Heckenlively essentially wrote it,” Mikovits says, “because I write like a scientist. We wrote it using the genre of flashback. He taped hours and hours of me telling the story as he asked me questions — because he’s trained as an attorney — and then he turned that into this suspense-thriller. Interestingly enough, it almost has to read like fiction because of the lawyers it took to … make sure we weren’t sued.”

What Are Retroviruses?

Before we go further, let’s review what a retrovirus is. A retrovirus is a ribonucleic acid (RNA) virus — in other words, a virus that contains RNA encoded genes rather than deoxyribonucleic acid (DNA). Using reverse transcriptase, the retrovirus is able to transform the single-stranded RNA into a double-stranded DNA.

When the retrovirus infects a host, it integrates its DNA into the DNA of the host cell, which allows the retrovirus to replicate itself and spread through the host. As more and more cells are infected, you become increasingly sicker. Mikovits explains:

“Humans have a DNA genome. Our blueprint is DNA. Retroviruses have an RNA genome, but they also are unique in the RNA family of viruses, where their RNA genome is reverse-transcribed. That is, written backwards by an enzyme unique to retroviruses called reverse transcriptase. That enzyme writes the RNA into DNA.

Then they have another enzyme called integrase. Integrase is like a pair of scissors that cuts open your DNA and then inserts the retrovirus, which is only about 8,000 base pairs, a very, very, very small virus, 50 to 100 nanometers on an electron micrograph. That piece of DNA — called a provirus — is now in the DNA of your cells forever. Every time your cells replicate, you make more viruses.”

Now, this DNA insertion has been ongoing throughout human history. According to Mikovits, about 10 percent of the human genome is retroviral in origin. These are called human endogenous retroviruses. These, however, differ in that they’ve been crippled in part by our DNA methylation machinery (which modulates genes expression and the human immune system — so that they can no longer make complete viruses and therefore cannot infect others.

However, when you’re infected with a retrovirus such as human T-lymphotropic virus (HTLV-1), HIV HBRV or Borellia as in chronic Lyme disease and develop DNA methylation and immune dysfunction, these endogenous retroviruses begin to be expressed, and this is yet another really important finding.

HIV — One Example of a Transmissible Retrovirus

One example of a transmissible retrovirus is the HIV virus, which can cascade into the clinical symptoms of acquired immunodeficiency syndrome (AIDS). HIV was discovered in 1982, and as mentioned above, was part of Mikovits’ early research work. Her book includes the history of that important discovery.

When Mikovits first began studying retroviruses, HIV/AIDS was completely unknown, but they suspected a retrovirus was at play because of how retroviruses affect the human immune system and lead to acquired immune deficiencies and cancers.

“You don’t just one day get this virus and you’re sick. In fact, we now know millions of people have HIV and will never develop AIDS. We talk about that in the book, because the book ultimately is one of hope that we fix HIV.

I can honestly tell you in 1999, when I was running the lab of antiviral drug mechanisms, I did not ever expect we would solve that problem. Now, AIDS patients on antiretroviral therapy are probably healthier and develop fewer cancers … than most of the rest of society.”

Some retroviruses, including XMRV (but not HIV), also infect your germ cells, which means they not only cause continuous infection in your body but also transfer to your offspring.

“XMRV, the xenotropic murine (mouse) leukemia retrovirus, is the mouse-related retroviruses that cause cancer and lots of neurological diseases. Those affect the stem cells, the egg, the sperm — every cell in your body. That was one of the big ‘Oh, my Gods,’ about our discovery,” Mikovits says.

When it comes to treatment, the key is to keep the virus silent, because when they’re not, each time your cells divide you’re making more retroviruses. For this, antiretroviral treatments are used, some of which will be discussed later in this article.

From AIDS to ME/CFS

After 9/11, Mikovits started working with a woman whose daughter was severely ill with chronic fatigue syndrome. “Basically, that was the first time I ever saw the disease called ME/CFS,” she says.

“This person was looking at a herpes virus known as human herpesvirus 6 (HHV-6). This is a virus prominent in people with Kaposi sarcoma, [which] became associated with HIV and AIDS. Dr. Patrick Moore and Dr. Yuan Chang [discovered] that Kaposi sarcoma was actually caused by a herpes virus — then known as Kaposi sarcoma herpes virus; now, it’s HHV-8.

Because the immune system is crippled, you wake up the sleeping herpes viruses. People with autism, ME/CFS and cancers have a lot of chronic active infections, so we often see the Epstein-Barr virus (EBV) associated with outbreaks of ME/CFS …

This woman introduced me to Dr. Dan Peterson and Annette Whittemore in Incline Village, Nevada, where he had been studying outbreaks of ME/CFS for probably 25 years. He said he had a bank of samples. We went up there. I met all the patients.

I interviewed them in great length and developed a hypothesis, which had actually been shown before by Elaine Defreitas, Ph.D., another scientist many years earlier …

Defreitas had isolated retroviruses from patients with ME/CFS. A doctor … named Sidney Grossberg had also isolated retroviruses from at least one patient with ME/CFS. So, the retroviral hypothesis wasn’t new. Everything about it fit …

One of the most severely injured patients at that time was Whittemore’s daughter, Andrea. That summer (2006), I went up there … and started studying it … I used the systems biology approach, because there’s a lot of heterogeneity.

We know AIDS patients who have HIV and will never get AIDS … I interviewed patients in Peterson’s office all summer and took blood, urine, saliva and all kinds of samples to isolate that virus, which is what you need to do to show it’s associated with a disease.”

The Discovery of Infectious Retroviruses

Eventually, she brought together several of her former and current colleagues who were world experts in HIV sequencing to look at ME/CFS. Among them was the world’s leading electron microscopist, Kunio Nagashima, who has done the electron micrographs of every family of human retroviruses discovered: the human beta retrovirus, human delta virus, lenti-virus (such as HIV) and gamma retroviruses.

Working in collaboration with the Cleveland Clinic, Mikovits and her team isolated the virus and spent the better part of 2008 and 2009 putting a paper together, proving the XMRV retrovirus was infectious and transmissible and not just another crippled human endogenous retrovirus.

“To our horror, we learned these [retroviruses] could be aerosolized. This was in 2011 … That was really the first nail in my coffin. Pun intended, because the national academy member, John Coffin, Ph.D. — who had told Frank Ruscetti, ‘There is no such thing as human retroviruses. Don’t study them’ — then made a fortune out of HIV and did everything he could to destroy me and the patients,” Mikovits says.

“Prior to publication in 2009, we wrote a patent on the detection of these retroviruses, these pieces and parts as contaminants of the cell cultures, of the cell lines from which we make vaccines. After they destroyed my reputation and career and forced the retraction of our paper from [the journal] Science, Coffin turned around and wrote a patent on the detection of these viruses in contaminating cell linings and contaminating biologicals in our labs.”

This PDF includes emails, letters and supporting documentation showing how the retraction of Mikovits’ Science paper was forced, after which Coffin filed his own patent for a detection method of the contaminants in cell lines used for vaccines and other biologicals. There’s also documentation detailing the scientific fraud Mikovits asserts in this interview.

Infectious Retroviruses May Contaminate Blood Supply and Vaccines

In her book, she also details how infectious retroviruses are still likely infecting many biological solutions used clinically today, such as vaccines and other therapies. To say that this is a concern would be an understatement. Children’s Health Defense discusses this, and more, in “Looking Back, Looking Forward: Cancer and Vaccines.”1 Mikovits explains:

“That was really at the heart of the big ‘Oh, my God.’ The worst I learned in this whole experience is how corrupt scientific journals are. In fact, Ruscetti now calls Science, that prestigious journal, ‘The National Inquirer,’ because they literally engineered the whole thing to destroy MEC/FS patients and any association this virus [XMRV] had with these diseases …

All of the studies showed that the control population was between 3.75 and 6.8 percent infected. When you do a study and there’s evidence of infection in 6 percent of the human population, that’s 25 million Americans. To put that in context, at the height of HIV/AIDS in 1995, it was 1 million Americans. It would crush our health care system if they had to pay for what they caused.”

The result of Mikovits’ findings was nothing short of personal devastation. Not only was her paper retracted by Science, she was even arrested for “stealing” her own lab notes. Charges were ultimately dropped, but the damage to her reputation was a done deal.

“Basically, our paper came out on October 8, 2009. It was literally like ‘the shot heard around the world.’ I was on the road every single day. Everywhere I went doctors were like, ‘She’s got it. She’s got it. She’s got it,’ and not just with MEC/FS but also with cancer, leukemia, lymphoma, with prostate cancer.

When you start looking at the inflammatory events in the acquired immune deficiencies, with autoimmune disease, with Lou Gehrig’s disease, the problem became this [retro]virus. Well, there’s no single virus. There’s no HIV. There’s a whole family of HIVs. There’s an HIV 1. There’s an HIV 2. There’s a strain A, B, C and D.

Why do we do influenza vaccines for this strain de jour or every year? [Because] there are strains of viruses. There are families of viruses … The second that we published this paper, we started working to get a diagnostic test for the blood supply to show it wasn’t contaminated, which, in fact, it was.

Later that year, the last talk I ever gave was on a science paper that came out September 22, 2011 … That talk was basically a debate for the evidence that there are human retroviruses of the XMRV family that aren’t VP62 (the infectious molecular clone, not the natural isolates of our paper).

We could show in the original paper that there was evidence of murine leukemia viruses, gamma retroviruses that were infectious and transmissible, just as we had said.

Coffin was on the other end of that debate. He said it was all a recombination event. He published a paper in 2013 saying, ‘When we worked with mouse cells, they expressed a lot of pieces and parts of retroviruses. This just happened to happen in the laboratory.’

[Hence, he claimed] that’s what we had isolated. [Coffin claimed] that what we were looking at were just contaminants in the laboratory. ‘It’s all a lab contaminant,’ [Coffin said], ‘You can all go home. You’re safe.'”

Massive Public Health Concerns Swept Under the Rug

As one might expect, Mikovits’ research caused massive concern in the professional community, because here was a newly identified, infectious and transmissible retrovirus that no one was screening for, and it was potentially contaminating 10 percent of the human blood supply. But rather than face the problem head on, it was rapidly swept under the proverbial rug.

“My mom was watching Good Morning America one morning. Across the bottom of the ticker tape said, ‘XMRV all a hoax’ … It was horrible. We started to realize our fake news and fake science.”

Today, the blood supply is unlikely to be contaminated, thanks to a decontamination procedure developed by a California-based company called Cerus and which Mikovits proved to inactivate XMRV, rendering it noninfectious.

Other biologicals, including vaccines, however, may not be routinely decontaminated using this process, in large part because they’re not required to do so, and drug companies are not liable for vaccine-induced harm. What’s more, decontaminating the vaccine may render it ineffective.

“It won’t work. It will no longer be a vaccine … The Cerus method cleans up Ebola. It cleans up Zika. It cleans up essentially any RNA viruses, including HIV and all three human retroviruses. The Cerus system is extremely valuable to cleaning up the blood supply.

But they cannot clean up the vaccines for another reason. If they do, they prove Andy Wakefield right. They prove me right. They prove they’ve got 25 million Americans, who they have to support for the rest of their lives and pay damages [to] …”

The Price of Making an Unpopular Scientific Discovery

On a personal level, Mikovits has taken an enormous personal hit. September 29, 2011, she was fired from the Whittemore Peterson Institute for insolence and insubordination, and was driven into bankruptcy after being falsely arrested for stealing her own lab notes. (She never was and to this day is not in possession of her notebooks or any of the two offices full of her work done in her entire career.)

She explains her firing saying that Whittemore had been selling a diagnostic test and the director of their for-profit commercial laboratory was using federal grant funds to do that work (with full knowledge and under the direction of Annette and Harvey Whittemore), which is misappropriation of federal funds. Mikovits became aware of this in August that year, and wrote him off the grant.

“The Whittemores basically fired me immediately in an attempt … to get this scientist, Vince Lombardi, Ph.D. … to recreate the work while I was out of town and say I was a lunatic — that he’d been doing the work all along, and he hadn’t misappropriated any of the funds.

They fired me on September 29 and immediately locked down the entire university to me or my staff … The insolence and insubordination was I had refused a direct order to misappropriate federal funds, basically. I wasn’t ever going to do that. The insolence I’m trying to learn not to do, because it probably would have gone a lot better for me if I didn’t say ‘F-you,’ at the same time …

It was September 22, 2011, when I gave my last talk. They had three weeks to get a Science paper out there that would destroy my reputation in the ME/CFS community … Ruscetti had to sign that paper, or he and Sandy Ruscetti would be fired … [and] lose their entire retirement, which is 75 years.

That was one of the few times I sobbed. I was sitting in my bed screaming …It was 6 o’clock in the morning. They were on the East Coast and they needed to get this paper published fast by Science.

I called the Ruscettis and said, “Frank, they agreed to change the language. They agreed to change the title. They agreed it wasn’t an association study … [they say] we didn’t have a diagnostic test. Either way, the Whittemores are going to kill me because they’re selling the diagnostic test.’

So Frank [Ruscetti] signed the paper. They didn’t change the wording. [What they did] is pure fraud. Here, the head of the National Heart, Lung, and Blood Institute published pure fraud in the journal Science, just as two years later, Ian Lipkin published pure fraud. It is fake news. It is so corrupt, everything about it.

It’s not [the researchers]. It’s the top of the line. It’s Dr. Tony Fauci. We’re only allowed to make incremental advances. When you make a discovery of this nature, it changes all of everything. This is misogyny … This is a bunch of little boys … fighting over who gets credit, while the world dies, while you kill an entire continent.

That’s why I do shows like this. Because we’re going to teach doctors. When doctors understand the science — and they’re coming around a lot — because the science is there. Nothing about our paper, except the sequence of the virus, has ever been wrong. We knew that in the beginning.”

Individuals Infected With Retroviruses Should Avoid Vaccinations

According to Mikovits, retroviruses such as XMRV affect entire families, as it can be transmitted to your offspring. Many of these families also have children with autism, which Mikovits believes may be connected to the retrovirus. The question is, what can you do if you’re infected? For starters, Mikovits recommends avoiding vaccinations.

“Until 2011, not inconsequentially, we didn’t vaccinate AIDS patients the same way. It’s in the book. You don’t vaccinate the immune-compromised … By definition, you have an immune system that doesn’t work. Why would you vaccinate them? Why would you vaccinate somebody under 3 years old, who has an immune and detox systems that don’t work?

This was the key of the RNaseL story (a genetic susceptibility not to degrade RNA viruses), of the Thompson fraudulent paper [Editor’s note: This refers to William Thompson, Ph.D., a former senior scientist at the CDC’s National Center for Immunizations and Respiratory Diseases, who confessed he conspired to cover up links found between the MMR vaccine and autism].

All they had to do was wait for black boys to be 3 years old, and they would have been able to degrade the RNA virus. That’s criminal. That’s beyond comprehension …

The pearl of wisdom is this DNA methylation. Keep the violent virus silent … DNA methylation has to silence them. You can’t inject them in a vaccine. We’re injecting millions of pieces in parts of retroviruses in every vaccine, by definition (and admission).

I am working on an ongoing cancer lawsuit that says vaccines cause childhood cancer, a lymphoma. By these same mechanisms, you’ve destroyed the DNA methylation machinery’s ability [to silence the virus]. You’ve simply overwhelmed the substrate. You’ve overwhelmed the ability to methylate.

Every time those viruses integrate, you have a better chance at insertional mutagenesis. Don’t expose anybody to human (or animal) retroviruses. Use antiretroviral therapy, which are natural products … There are lots of natural products. We published on them. Those are actually therapy for these kids.

[A 100-year-old drug called Suramin] was one of the first antiretroviral therapies for HIV … [It] worked best against the murine leukemia virus-related viruses, against the mouse retroviruses, the gamma retroviruses …

[Dr. Robert] Naviaux [professor of medicine, pediatrics and pathology at University of California San Diego School of Medicine] did a small clinical trial.2 These kids got their life back.3 They started talking again. What did Bayer do? They stopped the trial and took the drug away from everyone. Now, you can’t get it …

We could help millions of people get over [autism]. But when you show cure, you know cause. That’s it. I would be right … Millions of people would get their lives back, and it’s all about money.”

XMRV Is a Significant Threat

As mentioned, there are several different retroviruses, which are part of four viral families (delta, lenti, beta and gamma). Aside from HIV and XMRV, there’s the human T-cell leukemia lymphoma virus (HTLV-1) family. There are five or six HTLV viruses, but HTLV-1 is the only one known to cause severe disease.

Human beta retrovirus is another virus associated with primary biliary cirrhosis. Many patients with MEC/FS also have family members with primary biliary cirrhosis. As for which one might be the most significant threat, Mikovits believes XMRV is among the most pressing, because while HIV is well-contained at present, XMRV is not, and it appears to play a significant role in diseases of methylation.

Disturbingly, they’re now using murine leukemia viruses as vectors for gene therapy and a novel cancer therapy called chimeric antigen receptor (CAR) T-cell therapy. In other words, they’re causing cancer and other retroviral illnesses.

“The same thing with Gardasil … We’re causing these diseases and we know it because we’re using these [retroviruses] as vectors. We don’t need infectious viruses. That’s one thing that’s really important to know. You don’t need infectious viruses if you’re injecting the provirus, or the pieces and parts. You inject it, past your immunity, past your gut, past RNA cell, past everything. You bypass the immune system. They don’t need to be infectious.

All you need is an envelope to cause that prostate cancer. That’s a paper that was published 2013. In most of our studies, all we detected was the envelope. The envelope alone causes vasculitis … Another strain of XMRV gamma retrovirus from mice was identified by Gary Owens … associated with cardiovascular disease. This is just a nightmare that we’ve unleashed in our environment.”

Retroviruses and ME/CFS

According to Mikovits, 6 to 8 percent of the general population are infected with infectious and transmissible XMRV-retroviruses, and in the chronic fatigue population, that prevalence shoots up to about 30 to 40 percent. As with HIV, antiretroviral therapies can be very helpful in the treatment of ME/CFS, including low-dose naltrexone.

“You have to silence the other pathogens, so taking care of mycoplasma, taking care of mold, absolutely supporting the gut microbiome [will help],“ Mikovits says. “We learned with AIDS and cancer patients that if they don’t have the diversity in the microbiome, just like in autism, just like in MEC/FS, it’s because the retrovirus is causing leaky gut …

The nonspecific inflammation [is] the retroviruses. If you keep the gut healthy, you can heal. The primary is the diversity in the microbiome, or you can’t respond to the drugs. There’s a lot of hope. That’s what we end the show with. There are therapies. We could fix this tomorrow. That’s why I do it.”

To learn more, be sure to pick up a copy of “Plague: One Scientist’s Intrepid Search for the Truth About Human Retroviruses and Chronic Fatigue Syndrome (ME/CFS), Autism and Other Diseases,” which reads more like a fictional thriller than a nonfictional book about the science of disease.

________________

For More:  https://madisonarealymesupportgroup.com/2017/10/15/vaccines-and-retroviruses-a-whistleblower-reveals-what-the-government-is-hiding/

https://madisonarealymesupportgroup.com/2018/03/01/vaccines-could-contribute-to-disease-epidemics-due-to-retrovirus-contamination/

https://madisonarealymesupportgroup.com/2018/06/23/the-role-of-retroviruses-in-chronic-illness-a-clinicians-perspective/

They should make Mikovits’s book into a movie.  It’s beyond belief.

 

 

https://rawlsmd.com/webinars/pain-solution/

52d2052a-webianr-title-desktop_0ig08z0ig08y000000

The Pain Solution with Dr. Bill Rawls

The sensation of pain serves the vital purpose of signaling the brain that something is wrong and requires attention and healing. But when pain is chronic and seems to have no identifiable cause, the brain doesn’t know how to restore health — and neither do most medical experts.

Join a live webinar with best-selling author Dr. Bill Rawls, who has studied the causes and symptoms of fibromyalgia, chronic Lyme disease, and chronic fatigue syndrome extensively.

He’ll explore the underlying forces that drive chronic pain and natural ways to resolve them, so you’re not just managing pain, but overcoming it.

PLUS: Have your questions ready for a LIVE Q&A on chronic pain and related illnesses including fibromyalgia, Lyme disease, and chronic fatigue syndrome with Dr. Rawls.

  • Presented by Dr. Bill Rawls and Carin Gorrell
  • Tuesday, December 11
  • 8pm EST
  • Webinar can be viewed on any device

RESERVE MY SEAT »

In this webinar, Dr. Rawls will also discuss:

  • The causes, characteristics, and biology of different types of pain
  • How your microbial burden impacts levels of pain-causing neurotransmitters and hormones
  • How CBD (cannabidiol) moderates the endocannabinoid system to reduce pain
  • Additional natural remedies for addressing underlying causes of pain and delivering both immediate and long-term relief
  • The four primary lifestyle factors that amplify pain
  • Numerous insights and answers during the LIVE Q&A with Dr. Rawls

 

https://www.galaxydx.com/uncategorized/first_tbdworkinggroup_post/

Last month we were excited to see the first report to Congress from the Tick-Borne Disease Working Group. This post kicks off a series that will break the report down into sections based on the group’s major findings. The series will run through the month of December here on the Galaxy Diagnostics blog.

The Tick-Borne Disease Working Group was established by the 21st Century Cures Act, signed into law in 2016. More than 300 pages long, the Act was a sweeping response to many issues in health care brought up from within health care businesses and by members of the public. Some of these health care issues had touched legislators personally, including tick-borne disease.

The working group is a diverse collection of federal and public individuals who came together to combine information from many areas of expertise.  Federal members include representatives of major institutions in health care including the Food and Drug Administration (FDA), the U.S Department of Health and Human Services (HHS) and even the Department of Defense (DoD). Public members include representatives from major research institutions, independent specialists, scientists, and patient advocates. In total, 65 people representing a variety of stakeholders serve on either the main working group or one of the six sub-committees.

The report they have developed was paid for by the people of the United States and belongs to everyone. We have attached to this post the “Core Values to Achieve One Shared Vision” graphic and the patient stories. You can share these pages to raise awareness of tick-borne disease in your community.

The core values statement responds to many of the frustrations patients have had about how tick-borne disease awareness, diagnosis, and treatment are approached by the public health and health care provider communities. Patients have often expressed a sense that they are not being heard and that their health care issues are not being properly addressed, resulting in increased economic burden and a feeling of helplessness.

In this report, the working group clearly states that a renewed collaborative ethos incorporating the experiences and expectations of patients is required to move forward. The values they cite are: respect, innovation, honesty & integrity, excellence, compassion, collaboration, and accountability.

Future posts in this series will discuss issues related to disease surveillance and access to care as well as how the elements of the report come together to look toward improved prevention efforts.

The full report can be accessed here. At that link you can also find out more information about the working group and find a link to the full text of the 21st Century Cures Act.

Sign Up to Receive Blog Updates!  (Click on top link)

 

https://www.lymedisease.org/hhs-lyme-innovation-speech-using-mylymedata-to-build-a-research-engine/  December 5, 2018

LYMEPOLICYWONK: Using MyLymeData to Build a Research Engine

 

Yesterday, I was honored to speak at the US Department of Health and Human Services’ Lyme Innovation Roundtable, about the need to build the research capacity of Lyme patients to create sustainable change and accelerate research.

To do this, we must embrace big data, precision medicine, and patient-centered research. You can watch a video of my presentation below.

Unacceptably high treatment failure rates in Lyme disease

Unacceptably high treatment failure rates in Lyme disease and in early Lyme disease –roughly 35% in a 2013 study by Dr. Aucott-and even higher rates for those diagnosed late—mean that many patients remain ill. (Aucott 2013) In our published studies, patients with chronic Lyme disease report being ill for more than 10 years. (Johnson 2011)

In addition to the human toll this exacts, this also makes it a costly problem to ignore.  According to a CDC study by Dr. X. Zhang the cost of late or chronic Lyme disease is 12 times higher than the cost of treating early disease —about $24,000 per person/per year when adjusted for inflation. (Zhang 2006)

And we can’t make the progress we need with the traditional way of doing research—one sequential randomized controlled trial followed by another.  It simply takes too long, costs too much, and doesn’t apply to most people, as Dr. Rob Califf at the FDA often points out.

For example, the NIH funded Lyme trials took 2.5 to 5 years to complete recruitment alone and most patients were screened out. Hence, the Klempner study, screened out 97% of those who applied. But look at the top bar—one of our published studies—where it took 6 months to recruit over 3,000 patients. (Krupp, 2003; Klempner 2001; Fallon 2008; Johnson 2014)

Big Data and Lyme Disease Research

Today with big data, we can and must accelerate the pace of clinical research and include real world patients.

But it is important to recognize that research orphaned diseases—like Lyme disease—require more targeted concerted research efforts. It requires that disease communities shoulder more of the research burden early on by collaborating with others to build a knowledge base, and identify biomarkers and treatment endpoints. This approach accelerates the research process so that industry is stepping into the disease later in the process when many of the challenges have been identified and resolved. It also de-risks the investment of time and money that industry must expend to develop better diagnostics and more effective treatments.

Dr. Stephen Groft, who until his retirement a few years ago headed the Office of Rare Diseases Research for the NIH, tells us how to do this. In his process—patient registries play a vital role by linking with biorepositories, helping develop the disease knowledge base, shaping clinical trial hypothesis, speeding up recruitment times, expediting FDA approval and reducing the burden of post approval studies. (Groft 2014)

Patient Registries Play A Pivotal Role

Patient registries play a pivotal role in Groft’s research engine because patients have access to sources of information that other stakeholders do not. They are the monkeys in the middle who hold the key to unlocking data silos—such as:

  • electronic health records,
  • insurance records,
  • biorepository sample results,
  • lab results and
  • of course, the information that can only be gleaned from patients—their symptoms and their response to treatment.

The bottom line is that patients have more complete information about their health than any other stakeholder, and as Eric Topol, Editor in Chief at Medscape points out “given the appropriate tools, [patients] represent [the] true “blockbuster” potential for improving their outcomes.”(Topol 2017)

MyLymeData – Largest Study Of Lyme Disease

LymeDisease.org has been conducting big data research using patient generated data for over 10 years. We published our first study on Access to Care in 2011 and in 2014 we published our Quality of Life study. (Johnson 2011; Johnson 2014) In 2015, we launched MyLymeData, our patient registry and research platform. With over 12,000 patients enrolled, today, it is the largest observational study of Lyme disease ever conducted—and actually one of the largest patient driven registries in the nation—for any disease. We have patients enrolled from every state in the nation and have collected over 2.5 million data points.

We are collaborating with researchers from the University of Washington and from UCLA—the UCLA researchers were awarded a grant from the National Science Foundation to pursue their research using the data from the registry.

We have also collaborated with the National Disease Research Interchange–the leading source for research tissues in the nation–and with one of the sponsors of the HHS Lyme Innovation conference –the Bay Area Lyme Foundation on a tissue specimen biorepository. This is the type of collaboration that is essential to build out a big data research engine and accelerate research in Lyme disease. All of these efforts align with Groft’s research engine components.

First Lyme Disease Study Published Using Registry Data

This year we published our first study using registry data. This study focuses on another component of the engine—the development of clinical treatment endpoints

The outcome measure to determine success in past treatment trials for late/chronic Lyme disease has been the average treatment response. But average treatment response is inherently flawed as an outcome measure because it ignores individual treatment response variation. Think of it this way– if one person gets better and another gets worse, their responses cancel each other out– on average.

Other diseases—like cancer and tuberculosis—identify and learn from high treatment responders.  They are called super-responders.  But to do this you need large samples and you need to be able to really hone in on individual treatment response variation at a highly granular level to identify how different subgroups of patients respond.

We used a widely recognized validated outcome measure called the Global Rating of Change scale. You simply ask a patient: “would you say that since you started treatment you are better, worse, or unchanged?” Those who said they were better or worse, are asked how much better or worse on a scale ranging from hardly better at all to a very great deal better. “On average” there was not much treatment response for the group as a whole, but individual treatment response varied widely.

Because this sample was so large—close to 4,000 and because the question was so granular—essentially a 15 point scale—we could really look at treatment variation within subgroups.  This allowed us to identify a group of high treatment responders—about 34%–who reported improving moderately to a very great deal.

Identifying high treatment responders is important in Lyme disease so that we can learn from their success and look at the factors that may have contributed to that success—for example, time to diagnosis or type of treatment. It is also the first step in moving Lyme disease toward personalized medicine and individualized care.

Another key value of this global rating of change scale outcome measure is that it can be asked by a patient registry, by a healthcare provider, or by a researcher in a controlled trial.  This means it can bridge different types of research and create interoperability of data—which helps fuel that research engine we are trying to build to accelerate research.

We are excited with the progress we have made with MyLymeData and the promise of big data and patient-centered research to accelerate the pace of research. We believe that Lyme communities need to build the components of an effective research engine by using MyLymeData, developing biorepositories, identifying biomarkers for the disease, compiling a knowledge base for the disease, and identifying clinical endpoints for trials that are relevant to patients. It is only by doing this that we can create the future that patients need in Lyme disease.

If you are a patient who is not enrolled in MyLymeData,  please enroll today. If you are a researcher who wants to collaborate with us, please contact me directly.